| 13/08/24 | 07:00:04 | 13 Aug 2024 | | Cancellation - Destiny Pharma plc |
| 12/08/24 | 07:00:01 | 12 Aug 2024 | | Last Day of Dealings on AIM |
| 05/08/24 | 11:58:21 | 5 Aug 2024 | | Director/PDMR Shareholding |
| 05/08/24 | 07:00:10 | 5 Aug 2024 | | XF-73 prevents bacterial invasion of bloodstream |
| 31/07/24 | 11:00:05 | 31 Jul 2024 | | Result of GM and Cancellation of Trading on AIM |
| 22/07/24 | 07:00:10 | 22 Jul 2024 | | Treatment of XF-73 Nasal reduces antibiotic use |
| 15/07/24 | 07:00:06 | 15 Jul 2024 | | Proposed Cancellation of Admission to Trading |
| 20/06/24 | 07:00:05 | 20 Jun 2024 | | Exercise of Options and Total Voting Rights |
| 18/06/24 | 07:00:08 | 18 Jun 2024 | | Efficacy of XF-70 in Fungal Skin Infections |
| 12/06/24 | 12:16:42 | 12 Jun 2024 | | Result of Annual General Meeting |
| 12/06/24 | 11:00:00 | 12 Jun 2024 | | 2024 Annual General Meeting and Statement |
| 11/06/24 | 07:00:04 | 11 Jun 2024 | | Destiny Pharma's XF-73 Nasal Awarded MHRA ILAP |
| 24/05/24 | 07:00:05 | 24 May 2024 | | Exercise of Options and Total Voting Rights |
| 09/05/24 | 14:35:50 | 9 May 2024 | | Posting of Annual Report and Notice of AGM |
| 25/04/24 | 07:00:08 | 25 Apr 2024 | | Full year results and review of strategic options |
| 08/04/24 | 07:00:08 | 8 Apr 2024 | | Notice of Full Year Results |
| 19/03/24 | 14:47:23 | 19 Mar 2024 | | Exercise of Options and Total Voting Rights |
| 31/01/24 | 07:00:08 | 31 Jan 2024 | | Clinical development update |
| 22/01/24 | 07:00:11 | 22 Jan 2024 | | Appointment of Nominated Adviser and Sole Broker |
| 04/01/24 | 07:00:03 | 4 Jan 2024 | | Year End Business Update |
| 20/10/23 | 07:00:07 | 20 Oct 2023 | | Grant of Share Options |
| 19/10/23 | 07:00:12 | 19 Oct 2023 | | Director/PDMR Shareholding |
| 17/10/23 | 07:01:03 | 17 Oct 2023 | | XF Pipeline Update Meeting |
| 17/10/23 | 07:00:09 | 17 Oct 2023 | | Publication of new microbiological data for XF-73 |
| 10/10/23 | 07:00:11 | 10 Oct 2023 | | Director/PDMR Shareholding |
| 04/10/23 | 12:34:01 | 4 Oct 2023 | | Director/PDMR Shareholding |
| 27/09/23 | 07:00:10 | 27 Sept 2023 | | Notice of XF Pipeline Update Meeting |
| 20/09/23 | 07:00:06 | 20 Sept 2023 | | Interim Results |
| 23/08/23 | 07:00:06 | 23 Aug 2023 | | Notice of Interim Results |
| 31/07/23 | 12:01:33 | 31 Jul 2023 | | Publication of new data for XF-73 |
| 25/07/23 | 07:00:06 | 25 Jul 2023 | | Appointment of new Chairman |
| 19/07/23 | 12:55:19 | 19 Jul 2023 | | Board changes including appointment of new CEO |
| 07/07/23 | 07:00:03 | 7 Jul 2023 | | Exercise of Options and Total Voting Rights |
| 06/07/23 | 07:00:10 | 6 Jul 2023 | | Positive findings from recent SAB meeting |
| 29/06/23 | 07:00:02 | 29 Jun 2023 | | Business Update |
| 26/05/23 | 15:27:34 | 26 May 2023 | | Director/PDMR Shareholding |
| 26/05/23 | 07:00:06 | 26 May 2023 | | Director Dealing |
| 25/05/23 | 12:23:40 | 25 May 2023 | | Result of Annual General Meeting |
| 25/05/23 | 07:00:10 | 25 May 2023 | | Dr Debra Barker Appointed Interim CEO |
| 12/05/23 | 12:24:48 | 12 May 2023 | | Grant of Share Options |
| 02/05/23 | 07:00:09 | 2 May 2023 | | Positive results from SPOR-COV® research |
| 26/04/23 | 16:10:41 | 26 Apr 2023 | | Posting of Annual Report and Notice of AGM |
| 26/04/23 | 10:05:07 | 26 Apr 2023 | | Exercise of Options and Total Voting Rights |
| 13/04/23 | 07:00:04 | 13 Apr 2023 | | Audited results for year ended 31 December 2022 |
| 04/04/23 | 07:00:03 | 4 Apr 2023 | | Landmark data published on NTCD-M3 |
| 03/04/23 | 07:00:17 | 3 Apr 2023 | | Notice of Results and Investor Presentation |
| 24/03/23 | 07:00:01 | 24 Mar 2023 | | Landmark XF-73 Phase 2 data published in journal |
| 16/03/23 | 15:29:58 | 16 Mar 2023 | | Result of General Meeting and Total Voting Rights |
| 15/03/23 | 16:02:26 | 15 Mar 2023 | | Result of Open Offer |
| 06/03/23 | 10:50:01 | 6 Mar 2023 | | Exercise of Options and Total Voting Rights |
